328 related articles for article (PubMed ID: 26223134)
1. [Preparation and release behaviour of mesoporous silica/ethylcellulose sustained-release mini-matrix].
Wu QL; Quan GL; Hong Y; Wu LN; Zeng YM; Li G; Pan X; Wu CB
Yao Xue Xue Bao; 2015 Apr; 50(4):492-9. PubMed ID: 26223134
[TBL] [Abstract][Full Text] [Related]
2. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
3. Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: in vitro and in vivo evaluation.
Verhoeven E; Vervaet C; Remon JP
Eur J Pharm Biopharm; 2006 Jul; 63(3):320-30. PubMed ID: 16517135
[TBL] [Abstract][Full Text] [Related]
4. Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers.
Maleki A; Hamidi M
Expert Opin Drug Deliv; 2016; 13(2):171-81. PubMed ID: 26636904
[TBL] [Abstract][Full Text] [Related]
5. Influence of formulation and process parameters on the release characteristics of ethylcellulose sustained-release mini-matrices produced by hot-melt extrusion.
Verhoeven E; De Beer TR; Van den Mooter G; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2008 May; 69(1):312-9. PubMed ID: 18036793
[TBL] [Abstract][Full Text] [Related]
6. Formulation and In Vitro Characterization of Bioactive Mesoporous Silica with Doxorubicin and Metronidazole Intended for Bone Treatment and Regeneration.
Czarnobaj K; Prokopowicz M; Sawicki W
AAPS PharmSciTech; 2017 Nov; 18(8):3163-3171. PubMed ID: 28534298
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation.
Chen B; Wang Z; Quan G; Peng X; Pan X; Wang R; Xu Y; Li G; Wu C
Int J Nanomedicine; 2012; 7():199-209. PubMed ID: 22275835
[TBL] [Abstract][Full Text] [Related]
8. Hollow mesoporous silica as a high drug loading carrier for regulation insoluble drug release.
Geng H; Zhao Y; Liu J; Cui Y; Wang Y; Zhao Q; Wang S
Int J Pharm; 2016 Aug; 510(1):184-94. PubMed ID: 27262268
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
[TBL] [Abstract][Full Text] [Related]
10. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
Abd-Elrahman AA; El Nabarawi MA; Hassan DH; Taha AA
Drug Deliv; 2016 Nov; 23(9):3387-3398. PubMed ID: 27167529
[TBL] [Abstract][Full Text] [Related]
11. PVP VA64 as a novel release-modifier for sustained-release mini-matrices prepared via hot melt extrusion.
Li Y; Lu M; Wu C
Drug Deliv Transl Res; 2018 Dec; 8(6):1670-1678. PubMed ID: 29127610
[TBL] [Abstract][Full Text] [Related]
12. Ordered mesoporous silica modified with lanthanum for ibuprofen loading and release behaviour.
Goscianska J; Olejnik A; Nowak I; Marciniak M; Pietrzak R
Eur J Pharm Biopharm; 2015 Aug; 94():550-8. PubMed ID: 26170160
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation.
Waters LJ; Hussain T; Parkes G; Hanrahan JP; Tobin JM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):936-41. PubMed ID: 23954510
[TBL] [Abstract][Full Text] [Related]
14. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
[TBL] [Abstract][Full Text] [Related]
15. The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol.
Wang Y; Sun L; Jiang T; Zhang J; Zhang C; Sun C; Deng Y; Sun J; Wang S
Drug Dev Ind Pharm; 2014 Jun; 40(6):819-28. PubMed ID: 23594300
[TBL] [Abstract][Full Text] [Related]
16. Drug loaded and ethylcellulose coated mesoporous silica for controlled drug release prepared using a pilot scale fluid bed system.
Hacene YC; Singh A; Van den Mooter G
Int J Pharm; 2016 Jun; 506(1-2):138-47. PubMed ID: 27107901
[TBL] [Abstract][Full Text] [Related]
17. Dodecylamine Template-Based Hexagonal Mesoporous Silica (HMS) as a Carrier for Improved Oral Delivery of Fenofibrate.
Jadhav NV; Vavia PR
AAPS PharmSciTech; 2017 Oct; 18(7):2764-2773. PubMed ID: 28353172
[TBL] [Abstract][Full Text] [Related]
18. How Molecular Mobility, Physical State, and Drug Distribution Influence the Naproxen Release Profile from Different Mesoporous Silica Matrices.
d'Orey P; Cordeiro T; Lourenço MAO; Matos I; Danède F; Sotomayor JC; Fonseca IM; Ferreira P; Correia NT; Dionísio M
Mol Pharm; 2021 Mar; 18(3):898-914. PubMed ID: 33461296
[TBL] [Abstract][Full Text] [Related]
19. Adsorption onto Mesoporous Silica Using Supercritical Fluid Technology Improves Dissolution Rate of Carbamazepine-a Poorly Soluble Compound.
Gandhi AV; Thipsay P; Kirthivasan B; Squillante E
AAPS PharmSciTech; 2017 Nov; 18(8):3140-3150. PubMed ID: 28534299
[TBL] [Abstract][Full Text] [Related]
20. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica.
Wang Z; Chen B; Quan G; Li F; Wu Q; Dian L; Dong Y; Li G; Wu C
Int J Nanomedicine; 2012; 7():5807-18. PubMed ID: 23209366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
